1. Home
  2. MAIA vs XBP Comparison

MAIA vs XBP Comparison

Compare MAIA & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • XBP
  • Stock Information
  • Founded
  • MAIA 2018
  • XBP N/A
  • Country
  • MAIA United States
  • XBP United Kingdom
  • Employees
  • MAIA N/A
  • XBP N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • XBP Business Services
  • Sector
  • MAIA Health Care
  • XBP Consumer Discretionary
  • Exchange
  • MAIA Nasdaq
  • XBP Nasdaq
  • Market Cap
  • MAIA 46.7M
  • XBP 40.1M
  • IPO Year
  • MAIA 2022
  • XBP N/A
  • Fundamental
  • Price
  • MAIA $2.15
  • XBP $1.10
  • Analyst Decision
  • MAIA
  • XBP
  • Analyst Count
  • MAIA 0
  • XBP 0
  • Target Price
  • MAIA N/A
  • XBP N/A
  • AVG Volume (30 Days)
  • MAIA 79.7K
  • XBP 16.4K
  • Earning Date
  • MAIA 05-13-2025
  • XBP 03-19-2025
  • Dividend Yield
  • MAIA N/A
  • XBP N/A
  • EPS Growth
  • MAIA N/A
  • XBP N/A
  • EPS
  • MAIA N/A
  • XBP N/A
  • Revenue
  • MAIA N/A
  • XBP $142,772,000.00
  • Revenue This Year
  • MAIA N/A
  • XBP N/A
  • Revenue Next Year
  • MAIA N/A
  • XBP N/A
  • P/E Ratio
  • MAIA N/A
  • XBP N/A
  • Revenue Growth
  • MAIA N/A
  • XBP N/A
  • 52 Week Low
  • MAIA $1.40
  • XBP $0.79
  • 52 Week High
  • MAIA $5.99
  • XBP $4.33
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 70.43
  • XBP 47.59
  • Support Level
  • MAIA $1.51
  • XBP $1.00
  • Resistance Level
  • MAIA $1.61
  • XBP $1.16
  • Average True Range (ATR)
  • MAIA 0.12
  • XBP 0.10
  • MACD
  • MAIA 0.06
  • XBP -0.00
  • Stochastic Oscillator
  • MAIA 90.91
  • XBP 41.78

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About XBP XBP Europe Holdings Inc.

XBP Europe Holdings Inc is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and operations partner for its clients' strategic journeys and streamlining their complex, disconnected payment processes. It has two segments Bills and Payments focusing on optimizing how bills and payments are processed by businesses of all sizes and industries and Technology focuses on sales of recurring and perpetual software licenses and related maintenance, hardware solutions, and related maintenance and professional services. It generates the majority of its revenue from the Bills and Payments segment.

Share on Social Networks: